Why the study?
Does a fixed-dose regimen of oral apixaban alone safely and effectively treat acute venous thromboembolism compared to conventional therapy?
Does a fixed-dose regimen of oral apixaban alone safely and effectively treat acute venous thromboembolism compared to conventional therapy?
Oral apixaban is noninferior to conventional therapy for treating acute venous thromboembolism while significantly reducing bleeding risk.
Supports apixaban monotherapy for acute VTE; confirms RCT evidence favoring simplified regimens with less bleeding.
A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: